The mTORC1 signaling pathway is constitutively activated in almost all acute myelogenous leukemia (AML) patients. We conducted a phase Ib trial combining RAD001 (everolimus), an allosteric inhibitor ...

The Company has submitted a supplemental New Drug Application (sNDA) seeking the approval of revumenib for the treatment of R/R mNPM1 AML. The sNDA has been granted Priority Review by the FDA and ...

Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML). This is an ASCO ...

Please provide your email address to receive an email when new articles are posted on . Down syndrome remained a significant risk factor for pediatric leukemia, especially acute myeloid leukemia, ...

CLEVELAND, May 31, 2017 /PRNewswire-USNewswire/ -- AML RightSource, a Gabriel Partners Company, is pleased to announce its affiliate membership with the Association of Certified Financial Crime ...

Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison. Prospective assessment of ...

– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – ...

GENEVA, Sept. 25, 2024 /PRNewswire/ -- BSV Association and Global Ledger are pleased to announce their collaboration to bring full support and AML Solutions for the BSV network and community. As a new ...

AML Watcher joins the Hong Kong FinTech Association, strengthening AML compliance innovation and expanding its global fintech Network in the APAC region. “This partnership connects us to a rich ...

AML Watcher joins the Singapore FinTech Association to drive AML innovation, expand globally, and simplify compliance for financial institutions. This partnership reflects our belief that meaningful ...